Antibody–Drug Conjugates for the Treatment of B-cell Non–Hodgkin's Lymphoma and Leukemia Yu-Waye Chu; Andrew Polson Disclosures Future Oncol. 2013;9 (3):355-368.

Cellular therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), have revolutionized the treatment of various B-cell non-Hodgkin lymphomas. A number of agents ...

Single B-cell technologies have emerged as powerful screening tools to accelerate antibody discovery, offering R&D teams the potential to interrogate millions of individual antibody-secreting ...

A previous analysis of B cell receptor (BCR)-derived HLA-DR epitopes present in memory antibody repertoires from seven healthy human donors revealed a decrease in donor-specific epitope content with ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types, risk factors, and prognosis.

B-lymphocytes are white blood cells that produce antibodies to fight infections and viruses. However, in B-PLL, the cell growth is out of control, and the lymphocyte count is excessive.

By eliminating conventional antibody interference and faithfully replicating human immunoglobulin gene expression, the platform optimizes B cell development and generates robust immune responses, ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases ...

The antibody, called IPH6501, is now being evaluated in a phase 1/2 trial in patients with relapsed or unresponsive B cell non-Hodgkin lymphoma.

Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen.

Scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy cancer cells or HIV ...